Page last updated: 2024-11-13
spiruchostatin b
Description
spiruchostatin B: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
spiruchostatin B : A spiruchostatin with molecular formula C21H33N3O6S2 originally isolated from a Pseudomonas culture broth. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 24854391 |
| CHEBI ID | 90235 |
| SCHEMBL ID | 15926378 |
| MeSH ID | M0522912 |
Synonyms (6)
| Synonym |
|---|
| spiruchostatin b |
| SCHEMBL15926378 |
| CHEBI:90235 |
| (-)-spiruchostatin b |
| (1s,5s,6r,9s,15e,20r)-6-[(2s)-butan-2-yl]-5-hydroxy-20-methyl-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docos-15-ene-3,8,18,21-tetrone |
| Q27162416 |
Research Excerpts
Overview
Spiruchostatin B (SP-B) is a potent histone deacetylase (HDAC) inhibitor. The pharmacological effects of SP-B are also attributed to its ability to produce intracellular reactive oxygen species (ROS)
| Excerpt | Reference | Relevance |
|---|
| "Spiruchostatin B (SP-B), is a potent histone deacetylase (HDAC) inhibitor, in addition to HDAC inhibition, the pharmacological effects of SP-B are also attributed to its ability to produce intracellular reactive oxygen species (ROS), particularly H2O2. " | ( Low-dose spiruchostatin-B, a potent histone deacetylase inhibitor enhances radiation-induced apoptosis in human lymphoma U937 cells via modulation of redox signaling.
Jawaid, P; Katoh, T; Kondo, T; Li, P; Narita, K; Rehman, MU; Shimizu, T; Zhao, QL, 2016) | 1.88 |
| "Spiruchostatin B (SP-B) is a potent histone deacetylase (HDAC) inhibitor that has potential for the chemotherapy of leukemia. " | ( Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells.
Ishikawa, M; Kanno, S; Katoh, T; Maeda, N; Tomizawa, A; Yomogida, S, 2012) | 2.03 |
Roles (3)
| Role | Description |
|---|
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| EC 3.5.1.98 (histone deacetylase) inhibitor | An EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98). |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| spiruchostatin | A class of cyclodepsipeptides with a bicyclic skeleton containing a disulfide linkage originally isolated from a Pseudomonas culture broth. The class also includes semi-synthetic derivatives, and synthetic analogues. |
| organic heterobicyclic compound | |
| organic disulfide | Compounds of structure RSSR in which R and R' are organic groups. |
| macrocyclic lactone | Any lactone in which the cyclic carboxylic ester group forms a part of a cyclic macromolecule. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.68
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.68 (24.57) | | Research Supply Index | 2.40 (2.92) | | Research Growth Index | 5.08 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |